Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PDE11A | Q9HCR9 | 3/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2922786 | 0.89 | HTT (0.36) | MEN1KMT2ALMNAPDE11ACETP | |
| SCHEMBL3948726 | 0.89 | CETP (0.45) | MEN1KMT2ALMNACETPHRH4 | |
| SCHEMBL2920928 | 0.89 | ESR1 (0.36) | MEN1KMT2ALMNAPDE11ACETP | |
| SCHEMBL2916952 | 0.89 | PDE11A (0.42) | MEN1KMT2ALMNAPDE11AHRH4 | |
| SCHEMBL3027474 | 0.87 | CHRNA10 (0.37) | MEN1KMT2ALMNAPDE11ACETP | |
| SCHEMBL3022088 | 0.85 | MAPT (0.41) | MEN1KMT2ALMNAHRH4MAPT | |
| SCHEMBL2921386 | 0.80 | MAPT (0.47) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL2913055 | 0.80 | KHK (0.43) | MEN1KMT2ALMNACETPALDH1A1 | |
| SCHEMBL2923250 | 0.79 | KMT2A (0.41) | MEN1KMT2APDE11AMAPTALDH1A1 | |
| SCHEMBL13212462 | 0.76 | PDE11A (0.37) | MEN1KMT2APDE11AHRH4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354531-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| EP-1874781-B9 | DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2010-09-08 | — | — | EP | disclosed |
| US-20100197656-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7723341-B2 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| EP-1874781-B1 | DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-7511045-B2 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | DPYD, DHODH, FH | MEN1 2282/4885KMT2A 4426/4885LMNA 4499/4885 |
| US-20100197656-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | TPMT, MALT1, IL1B | MEN1 2098/4885KMT2A 4617/4885LMNA 4117/4885 |
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | DPYD, DHODH, DPM1 | MEN1 2070/4885KMT2A 4444/4885LMNA 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.